Eighty-eight children 0.5 t o 17 years of age (median. 9 years of age) received an unrelated donor marrow transplant for treatment of chronic myeloid leukemia (CML; n = 161, acute lymphoblastic leukemia (ALL) in first or second remission (n = 15) or more advanced stage (n = 28). acute myeloid leukemia (AML; n = 13). or other hematologic diseases (n = 16) between June 1985 and April 1993. All patients were conditioned with cyclophosphamide and total body irradiation and received a combination of methotrexate and cyclosporine as graft-versus-host disease (GVHD) prophylaxis. Fourty-six patients received transplants from HLAidentical donors and 42 patients received transplants from donors who were minor-mismatched at one HLA-A or B or D/DRB1 locus. The Kaplan-Meier estimates of disease-free survival and relapse were 75% and 0% for patients with GML, 47% and 20% for ALL in first or second remission, 10% and 60% for ALL in relapse or third remission, 46% and 46% for AML in first remission (n = 1) or more advanced disease (n = 12). and 29% and 69% for other diseases. HLA disparity was not significantly associated with lower disease-free survival, but the results suggest more relapses in HLA-matched recipients and there was significantly more transplant-related mortality in mismatched recipients (51% v 24%. P = .04). Most deaths were due t o infections associated with LLOGENEIC MARROW transplantation has become standard treatment for a variety of congenital and acquired disorders of the lympho-hematopoietic system and metabolism.'"' Because an HLA-identical sibling is available for less than 30% of potential transplant candidates, the use of alternative donors has been explored.'2"6 Transplants from HLA-matched unrelated donors became feasible once large registries of HLA-typed volunteers willing to donate bone marrow were established in the United States and in other countries, creating a global network of more than 1.7 million donor^.'^-'^ The probability of finding at least one HLA-A, B, DR-identical donor has increased at our center from 24% during the period from 1985 to 1988 to 61% in 1993, and the probability of reaching transplantation with marrow from an HLA-A, B, D/DRBl-identical donor has increased from 1 1 % to 29% during those same periods.16." However, transplants from unrelated donors are associated with a high incidence of graft-versus-host disease (GVHD), morbidity, and mortality. Survival after unrelated donor transplants is better in children than in adults.'8,20-22 This study evaluated the safety and efficacy of transplants from unrelated donors in children with myelodysplasia, leukemia, lymphoma, and aplastic anemia. acuteor chronic GVHD and occurred within the first 2 years after transplantation. Granulocyte engraftment occurred in all evaluable patients. Sixty-three percent of HLA-matched and 57% of HLA-mismatched recipients were discharged home disease-free at a median of 98 and 103 days. respectively, after transplantation (P = not significant [NSI). The incidence of grades Il-IV acute GVHD was 83% in HLAmatched and 98% in HLA-mismatched recipients (P = .009). The incidence of chronic GVHD was 60% in HLA-matched and 69% in HLA-mismatched recipients ( P = NS). One or multiple late adverse events such as cataracts, osteonecrosis of the hip or knee, restrictive or obstructive pulmonary disease, and hypothyroidism have occurred in l l of 33 (33%) surviving patients. Immunosuppression was discontinued in 58% of surviving patients, including all 12 patients surviving more than 3.2 years, all of whom have a Lansky or Karnofsky score of 100%. These data show that marrow transplantation from fully or partially HLA-matched unrelated donors can be effective therapy for children with hematologic disorders and that pretransplantation disease status and posttransplantation GVHD remain important factors affecting patient outcome. 0 7995 by The American Society of Hematology.
A MATERIALS AND METHODS

Patients
acuteor chronic GVHD and occurred within the first 2 years after transplantation. Granulocyte engraftment occurred in all evaluable patients. Sixty-three percent of HLA-matched and 57% of HLA-mismatched recipients were discharged home disease-free at a median of 98 and 103 days. respectively, after transplantation (P = not significant [NSI). The incidence of grades Il-IV acute GVHD was 83% in HLAmatched and 98% in HLA-mismatched recipients (P = .009). The incidence of chronic GVHD was 60% in HLA-matched and 69% in HLA-mismatched recipients ( P = NS). One or multiple late adverse events such as cataracts, osteonecrosis of the hip or knee, restrictive or obstructive pulmonary disease, and hypothyroidism have occurred in l l of 33 (33%) surviving patients. Immunosuppression was discontinued in 58% of surviving patients, including all 12 patients surviving more than 3.2 years, all of whom have a Lansky or Karnofsky score of 100%. These data show that marrow transplantation from fully or partially HLA-matched unrelated donors can be effective therapy for children with hematologic disorders and that pretransplantation disease status and posttransplantation GVHD remain important factors affecting patient outcome. 0 7995 by The American Society of Hematology.
regimens for conditioning and GVHD prophylaxis and were not included in this report. Patient disease and transplant characteristics are described in Tables  1 and 2 . For patients affected by acute leukemia, the remission number was defined by events in the marrow and extramedullary relapses were not counted as separate relapses. The time interval from the last marrow remission to transplantation did not consider intercurrent extramedullary relapses. Patients affected by acute lymphoid leukemia (ALL) or acute myeloid leukemia (AML) in first or second marrow remission, lymphoma in remission, chronic myelogenous leukemia (CML) in chronic or accelerated phase, and severe aplastic anemia (SAA) were considered as goodrisk patients, whereas ALL or AML in relapse or third remission, CML. in blast phase, lymphoma in relapse, juvenile CML (J-CML), subtypes of myelodysplasia (MDS) with excess blasts, and malignant histiocytosis in relapse were considered poor-risk patients.
Histocompatibility studies and donor selection. Unrelated donor and antigens were assigned as defined by the World Health Organization (WHO) HLA nomenclature committee.z6 HLA-DR typing was performed using nylon-wool-purified B cells in a modified microtoxicity cross-match a~say.2~ HLA-D region compatibility was defined by assigning "Dw" phenotyping with HLA-D homozygous typing cells (HTC) in a standard HLA-D typing assay.26 Beginning in 1990, HLA-D region compatibility was defined as identity for DRBl alleles by hybridization of polymerase chain reaction (PCR)-amplified DNA with sequence-specific oligonucleotide probes (SSOP)." Donor selection was based on matching for HLA-A, B and D, or DRBI. If an HLA-A, B, D/ DRBI-identical donor was not identified, the search was extended to include potential donors incompatible for no more than one antigen at HLA-A, B, or DR. Incompatibility for a single HLA locus was allowed if there was a HLA-A or -B disparity within a crossreactive group (eg, HLA-A23 and A24 or HLA-B7 and B27) or if there was HLA-Dw or DRBl disparity within the same DR type [eg, Dw4(DR4) v Dw14 (DR4), or DRB1*0401 (DR4) v DRB1*0402 (DR4)]. 25 Transplantation procedure. The FHCRC Institutional Review Board of the FHCRC approved the treatment protocols. Informed consent was obtained from all parents or guardians and from all patients 1 l to 18 years or age. Written informed assent was provided by children 7 to 11 years old. The conditioning regimens consisted of intravenous (IV) cyclophosphamide at the dose of 60 mg/kg/day administered for 2 days followed by total body irradiation at the dose specified in Table 2 .25 GVHD prophylaxis was a combination of IV methotrexate at 15 mg/m2 on day 1 and at 10 mg/m' on days 3 , 6 , and 1 1 and IV cyclosporine at 3 m@g/d beginning on day -1 and converted to 12.5 m@g/d orally (PO) when oral medication could be t0lerated.2~ Donor marrow was not T-cell-depleted before infusion.
Engraftment. Myeloid engraftment was defined to occur on the first of 3 consecutive days when the granulocyte count was greater than 0.5 X lo'&. Platelet engraftment was defined to be achieved on the first of 7 consecutive days when the platelet count was greater than SO X IOY& without transfusional support. To show donor engraftment in sex-mismatched transplants, peripheral blood lymphocytes and marrow cells were tested by in situ DNA hybridization with a Y-body-specific probe.'* If donor and recipient were sexmatched, chimerism was determined by restriction fragment length polymorphism (RFLP) analysis or by PCR of DNA sequences with a variable number of tandem repeats (VNTR).29,"' Acute and chronic GVHD. Acute and chronic GVHD were diagnosed and graded according to conventional criteria.'," All patients were considered evaluable for acute GVHD in time-dependent analyses. Primary treatment for acute GVHD consisted of glucocorticoids or monoclonal or polyclonal anti-T-cell antibodie~.""~ Occurrence of chronic GVHD was evaluated among patients who survived in remission at least 100 days after transplantation. GVHD assessment For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From was performed around day 100. Patients without evidence of extensive chronic GVHD were instructed to taper immunosuppressive therapy and discontinue it by day 180, whereas immunosuppressive therapy with cyclosporine, prednisone, or both was prescribed for at least an additional 9 months for patients with clinical extensive chronic GVHD.', 35 Quality of life. The Lansky Play Performance Scale was used to assess the overall performance status36; patients 17 years of age or older were assessed according to the Karnofsky Performance S~ale.3~ Patients alive at each complete year after transplant were considered evaluable for that year; the score was considered valid if assigned within 3 months before or after the exact evaluation data.
Statistical analysis. Results of the study were analyzed as of January 31, 1994. The x ' test was used to compare differences between proportions of patients. Transplant-related mortality, relapse, disease-free survival, and treatment failure were estimated according to Kaplan and Meier in a univariable Patients with severe aplastic anemia were excluded from the analysis of relapse. Onset of acute GVHD was defined by the first clinical sign of GVHD within 100 days; acute GVHD resolution was defined to occur on the first day of absence of GVHD involvement of the liver and the gut (bilirubin <2 mg/dL; diarrhea -4 0 0 mL/d) and no more than grade I GVHD involvement of the skin (maculopapular rash <25%) within day 100.' Onset of chronic GVHD was defined by the day of diagnosis of clinical extensive chronic GVHD; resolution of chronic GVHD was defined to occur on the first day without immunosuppression in absence of any evidence of GVHD. Prevalence curves of acute and chronic GVHD were c~nstructed.'~ The prevalence curve increases if new cases of GVHD occur or if patients without GVHD die, relapse, or reach their last follow-up. The prevalence decreases if GVHD resolves or if patients with active GVHD die, relapse, or reach their last follow-up.4o
The measures of outcome examined in multivariable analyses included granulocyte and platelet engraftment, acute and chronic GVHD, relapse, transplant-related mortality, and disease-free survival. Cox proportional hazards regression models were used to examine the association of various independent variables with the hazard rate of each outcome measure?' Independent variables tested for an association included risk group according to disease status (good v poor risk), HLA compatibility of the donor (matched v mismatched), patient age (entered as a continuous variable), and dose of cells infused (entered as a continuous variable). Acute and chronic GVHD were also analyzed as time-dependent covariates. For the endpoints of engraftment, patients who died or relapsed before engrafting were censored at death or relapse, whichever occurred first; for the endpoint of platelet engraftment, patients who were discharged from Seattle before engrafting were also censored at departure. For the GVHD endpoints, patients who relapsed or died without developing GVHD were censored at time of relapse or death. For the endpoint of relapse, patients who died in remission were censored at time of death. For the endpoint of transplantrelated mortality, patients who had recurrent disease were censored at relapse. To test the null hypothesis of no association of the independent variables with the hazard of an outcome measure, the Wald test from the Cox regression model was used. Corresponding estimates of relative risks ( M ) and their 95% confidence intervals (CI) were obtained from the parameter estimates of the independent variables. Cox models were fit when variables were included into the model if they were significantly associated or suggestive of being associated with the hazard of the outcome variable. The assumption of proportional hazards across risk group and across HLA compatibility with the donor was checked by testing the significance of a log (time) variable?' No model showed a significant departure from the assumption of proportional hazards. No adjustments were made for multiple comparisons in calculating reported P values.
RESULTS
Engrafhnent.
Eighty-two (93%) of 88 patients achieved a sustained granulocyte count greater than 0.5 X 109L at a median of 21 days (range, 11 to 37 days) after transplantation. Three of the remaining 6 patients had persistent malignancy and the other 3 died without evidence of malignancy within 24 days from transplantation. In the multivariable analysis, the time of granulocyte engraftment did not differ between HLA-matched and mismatched recipients (Fig 1A) and followed in close association the onset of acute GVHD (RR = 2.05; 95% CI, 1.12 to 3.74; P = .02; Table 3 ). A platelet count greater than 50 X 109L sustained for at least 7 consecutive days without transfusion support was achieved at a median of 23 days (range, 20 to 79 days) by 44 (50%) patients (Fig 2B, 0 ) . Platelet levels were less than 50 X lo9/ L for 17 (19%) patients when they were discharged home at a median of 104 days (range, 86 to 149 days), and 27 patients who relapsed or died before discharge home never recovered to levels greater than 50 X 109L (Fig 2B, 0) .
In the multivariable analysis, platelet engraftment was not significantly delayed in HLA-mismatched recipients (Fig  lB) , but was delayed in patients with acute GVHD (RR = .28; 95% CI, 0.14 to 0.59; P = .0008; Table 3 ). A higher marrow cell dose, tested as a continuous variable, correlated with faster recovery of granulocyte (RR = 1.07; 95% CI, 1.02 to 1.12; P = .004) and platelet (RR = 1.17; 95% CI, 1.03 to 1.11; P = .002) counts (Fig 2 and Table 3 ).
Hospitalization. Seventy-six percent of the patients were discharged alive and disease-free from the hospital after a median of 34 days (range, 19 to 137 days) after transplantation. Forty-eight (72%) children were readmitted to the hospital at least once, in most cases because of infection or GVHD. The average time of hospitalization at the transplant center was 57 days. Fifty-three (60%) children were discharged home disease-free at a median of 99 days (range, 38 to 214 days) after transplantation. The time of hospitalization was not significantly longer in HLA-mismatched recipients ( P = not significant [NSJ).
Acute GVHD. Thirty-eight (83%) of 46 matched and 41 (98%) of 42 mismatched recipients developed acute GVHD of grades 11-IV at a median of 13 days (range, 5 to 49 days) after transplantation (P = .009). Acute GVHD of grades I11
or IV occurred in 17 (37%) matched and 26 (62%) mismatched recipients and most often involved the skin (Table  4 ). The prevalence of acute GVHD of grades 11-IV peaked at 74% on day 25 for HLA-matched and at 92% on day 23 for HLA-mismatched recipients (Fig 3) . By the multivariable analysis, donor HLA disparity (RR = 1.82; 95% CI, 1.16 to 2.86; P = .009) and older patient age (RR = 1.05; 95% CI, 1.01 to 1.10; P = .02) were associated with an increased risk of acute GVHD of grades 11-IV (Table 3) . Of note, transplantation of a higher dose of nucleated marrow cells was not correlated with acute GVHD.
By day 100 after transplantation, among 38 HLA-matched recipients with acute GVHD, 8 relapsed, 3 died in remission, 22 achieved remission of acute GVHD, and 5 progressed to chronic GVHD; whereas among 41 HLA-mismatched recipients with acute GVHD, 5 relapsed, 9 died in remission, 19
For A days a f t e r t r a n s p l a n t a t i o n B days a f t e r t r a n s p l a n t a t i o n achieved remission of acute GVHD, and 8 progressed to chronic GVHD.
Chronic GVHD. Fifty-six of 88 (64%) patients were alive with donor engraftment and relapse-free at 100 days after transplantation. Clinical extensive chronic GVHD was identified in 15 (27%) patients by day 100 and eventually 21 (37%) patients developed clinical extensive chronic GVHD at a median of 170 days (range, 100 to 256 days) while tapering immunosuppression. No evidence of clinical extensive chronic GVHD occurred in 20 (36%) patients.
Prevalence of chronic GVHD peaked at 74% on day 445 in matched recipients and at 7 1% on day 256 in mismatched recipients (Fig 3) . In the multivariable analysis, the risk of chronic GVHD was not affected by HLA disparity, but was increased by older age (RR = 1.09; 95% CI, 1.02 to 1.16; P = .01; Table 3 ). Twenty-four (67%) patients with chronic GVHD survive, 2 relapsed, and 10 died in remission, whereas 9 (45%) patients without chronic GVHD survive, 11 relapsed, and none died in remission. Immunosuppression was discontinued after a median of 190 days (range, 179 to 292 days) in all 9 surviving patients who did not have chronic GVHD, after a median of 565 days (range, 278 to 934 days) in 10 of 24 surviving patients who had chronic GVHD, and continues after a median of 683 days (range, 353 to 1,172 days) for the remaining 14 patients. Beyond day 1,172, all survivors (n = 12) were free of GVHD and had discontinued all immunosuppression (Fig 3) .
Transplant-related mortality. Twenty-five (28%) patients died in remission at a median of 84 days (range, 14 to 777 days) and in all but 3 patients death was associated with acute (n = 12) or chronic (n = 10) GVHD. The primary cause of death is listed in Table 5 . The Kaplan-Meier estimate of transplant-related mortality was 24% for HLAmatched and 51% for HLA-mismatched transplants (Fig 4) . The multivariable analysis confirmed that the risk of transplant-related death was increased in HLA-mismatched transplants (RR = 2.44; 95% CI, 1.04 to 5.56; P = .04) and in patients with chronic GVHD (RR = 6.05; 95% CI, 1.37 to 26.6; P = .02; Table 3 ).
Relapse. Thirty of 84 (36%) children with malignancy relapsed at a median of 83 days (range, 13 to 407 days) after transplantation. Relapse occurred within 6 months in 24 patients and between 6 and 14 months in 6 patients. The Kaplan-Meier estimate of relapse according to type and stage of disease is shown in Fig 5B. Among good-risk patients, the Kaplan-Meier estimate of relapse was 36% in 16 matched and 0% in 16 mismatched transplants (Fig 6B) ; among poorrisk patients, the Kaplan-Meier estimate of relapse was 57% in 29 matched and 60% in 23 mismatched transplants (Fig  6B) . By the multivariable analysis, the risk of relapse was higher in patients with advanced disease (RR = 4.17; 95% CI, l S 8 to 11 .O; P = .0039) and lower in older patients (RR = 0.88; 95% CI, 0.81 to 0.95; P = .0011; Table 3 ). Three patients survive after relapse at 720, 725, and 794 days: 1 with AML has achieved a spontaneous remission after immunosuppressive therapy was discontinued and has stayed in remission for 19 months, 1 with AML has been in complete remission for 381 days after a second transplantation, and 1 with J-CML has survived in relapse for 15 months.
Disease-free survival. Thirty-three of 88 (38%) children
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From survive disease-free at a median of 844 days (range, 276 to 2,948 days) after transplantation. The Kaplan-Meier estimate of disease-free survival at 3 years was 75% for CML, 47% for ALL in first or second remission, 10% for ALL in relapse or third remission, 46% for AML in first remission (n = 1) or more advanced disease (n = 12). and 29% for other diseases ( Fig 5A) . Other diseases included 5 patients with MDS (3 relapsed, 1 died of transplant-related causes, and 1 is disease free), 4 with lymphoma (2 relapsed, 1 died of transplant-related causes, and 1 is disease-free), 2 with J-CML (both relapsed), 1 with malignant histiocytosis (died with persistent disease), and 2 with SAA (2 are disease-free). The Kaplan-Meier estimate of disease-free survival was 56% for good-risk HLA-matched, 47% for good-risk HLA-mismatched transplants, 30% for poor-risk HLA-matched, and 21% for poor-risk HLA-mismatched transplants (Fig 6A) .
The multivariable analysis confirmed that status of disease at transplantation was the only factor that could be found associated with a significant increase in the risk of treatment failure (RR = 2.25; 95% CI, 1.27 to 4.00; P = .0056; Table   3 ). Qualiv of life. Late adverse events have been evaluated among the 33 surviving patients. Seven children developed cataracts at a median of 491 days (range, 235 to 1,228 days). For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From BALDUZZI ET AL served. Lansky Play or Karnofsky performance scores were collected in 36 of 40 patients (90%) alive at 1 year; 9 had a score of 70% or 80% and 27 had a score of 90% or 100%. At the end of 2 years, 21 of 25 patients (84%) were evaluated; 2 had a score of 70% or 80% and 19 had a score of 90% or 100%. All 14 children surviving between 3 and 7 years reported a last score of 100%.
DISCUSSION
Chemotherapy or autologous marrow grafts could potentially cure only a small fraction of children in this study, ie, those with acute leukemia or lymphoma in first or second
On the other hand, marrow transplantation from an unrelated donor was the only curative option for patients with MDS or CML, for patients with acute leukemia or malignant histiocytosis who had failed chemotherapy, and for patients with SAA who had failed to respond to immunosuppressive therapy."'* Transplantation from either an HLA-A, B, DFU3l-identical or one locus-mismatched unrelated donor was successful in achieving 38% disease-free survival at 3 years in those children. Disease-free survival was as high as 75% in patients with CML, 47% in patients with ALL in first or second remission, and lower in other patients with more advanced diseases. Relapse was the primary cause of treatment failure, was more frequent in patients with advanced malignancy at the time of the transplant, and was worse in relapsed ALL. These results support the idea that patients should be referred for treatment as soon as it is evident that they have failed to respond to conventional therapy. Patients with J-CML and adult-type CML should y e a r s a f t e r t r a n s p l a n t a t i o n B y e a r s a f t e r t r a n s p l a n t a t i o n be referred at diagnosis. Until the role of chemotherapy is clearly defined for children with MDS, allogeneic transplant shortly after diagnosis remains the recommended approach for curing of these patients. Patients with A M L , ALL, or lymphoma should be referred early after a first relapse.
Studies from Seattle and the International Bone Marrow Transplant Registry have shown decreased relapse rates in patients receiving allogeneic compared with the rates in twin transplants and in allogeneic recipients who developed acute or chronic GVHD compared with those without GVHD, suggesting that genetic disparity and graft-versus-host reaction are associated with an antileukemic The probability of relapse in children with ALL in second remission was 26% in this study of unrelated transplants, 42% in HLAidentical sibling transplants, and about 70% in autologous consistent with the antileukemic activity of allogeneic grafts. The effect of genetic disparity appears to be less evident in patients with advanced disease, presumably because of a large tumor burden. The incidence of recurrent leukemia in children receiving transplants with ALL in relapse was 52% in this study of unrelated transplants, 62% in HLA-identical sibling transplants, and 80% in autologous Depleting mature donor T cells from the marrow inoculum is an effective means to decrease the incidence and severity of acute and chronic GVHD, but it has been associated with an increased risk of graft rejection and leukemia r e l a p~e .~'~~~ More intensive conditioning therapy administered before transplant, with the intent of increasing immunosuppression and antileukemic activity, has also resulted in more treatment-related toxicity.'5-53 Therefore, most transplantation grafts.4*45 protocols using T-cell depletion have not been successful in both decreasing GVHD and improving disease-free survival. Results from the Milwaukee transplant team, in which a limited degree of T-cell depletion has been used in association with posttransplantation immunosuppression, appear promising in having decreased transplant-related morbidity without having jeopardized disease-free survival.'s~m~21~s2
As opposed to the many difficulties encountered in optimizing the various components of a transplant protocol using T-cell depletion, the use of a non-T-cell depleted protocol, similar to the one we report here, is relatively simple and results have been quite consistent among different group^.'^*".^^ However, the safety of unrelated transplantation without T-cell depletion has been limited by morbidity and mortality from GVHD and related opportunistic infect i o n~.~~ In our study, transplant-related mortality during the first 100 days was 15% in patients with active acute GVHD and beyond the first 100 days it was 28% in patients who developed chronic GVHD. Fungal infections, predominantly caused by Aspergillus, were the most frequent cause of nonleukemic death. Therefore, decreasing the incidence of GVHD remains the major challenge. Current trials are being attempting to improve posttransplantation immunosuppressive prophylaxis by adding glucocorticoids or a human antiinterleukin-2 receptor Q chain monoclonal antibody to the combination of cyclosporine and methotrexate, or substituting FK-506 for cyclosporine.~*s7~s8
Data from related donor transplants show that the risks of graft failure and GVHD increase with HLA disparity but that the probability of disease-free survival is similar to HLAmatched sibling transplants if the degree of HLA incompati- bility is limited to one HLA 1 0 c u s . '~~~~~" Consistent results have been reported in unrelated donor transplants and are extended here, in which disease-free survival was not lessened by a minor HLA disparity at one locus, even if morbidity was in~reased.'~ First hospitalization and further readmission periods tended to be longer and the risk and severity of acute GVHD and transplant-related mortality were in-BALDUZZI ET AL creased by HLA mismatching. On the contrary, there was a suggestion of less relapse among HLA-mismatched recipients. If an HLA-minor mismatched graft is accepted for young patients with hematologic malignancies, the number of patients with a suitable unrelated donor can be increased from approximately 34% to 70%. 19 Chronic GVHD and complications related to its immunosuppressive treatment were the major determinants of late transplant-related morbidity and mortality. Beyond 100 days from transplantation, all nonleukemic deaths occurred within 2 years and only in patients with chronic GVHD. No patient developed chronic GVHD later than 9 months after transplantation. Immunosuppression was discontinued in more than half of surviving patients and in all 12 patients surviving beyond 3.2 years. Late adverse events have not affected the performance status of patients surviving more than 3 years, all of whom have a Lansky or Karnofsky score of 100% and have returned to a normal healthy life.
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